Answer
Based on physiological-based pharmacokinetic model simulations, ketoconazole, a strong CYP3A4 and P-gp inhibitor, may increase unconjugated MMAE exposure (AUC) from polatuzumab vedotin by 48%; concomitant use warrants caution and closer monitoring for toxicity.
Sources for this answer
- Polivy 30 mg and 140 mg powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 9Document updated
Sources checked